Amgen "market perform"

10.09.07 - Rodman & Renshaw

NEW YORK, September 10 (newratings.com) - Analyst Michael G King of Rodman & Renshaw maintains his "market perform" rating on Amgen Inc (AMGN).

In a research note published on September 7, the analyst mentions that the Cardiovacular and Renal Drugs Advisory Committee (CRDAC) is scheduled to meet shortly to establish a target or a range of hemoglobin level that a dialysis patient should meet before being administered ESAs. The analyst expects the meeting to result in a change in Amgen?s ESA product label.